XML 17 R6.htm IDEA: XBRL DOCUMENT v3.22.4
Consolidated Statements of Cash Flows - USD ($)
$ in Thousands
 6 Months Ended
Nov. 30, 2022
Nov. 30, 2021
Cash flows from operating activities:    
Net loss $ (21,490) $ (15,323)
Adjustments to reconcile net loss to net cash used in operating activities:    
Depreciation and amortization 15,478 14,276
Non-cash lease expense 1,248 1,209
Stock based compensation 6,374 5,437
Change in fair value of contingent consideration 1,857 804
Gain on contingent consideration for IPR&D Write-off (1,525) (2,259)
Change in accounts receivable allowances 392 16
Fixed and intangible asset impairments and disposals 87 97
Other (43) (78)
Changes in operating assets and liabilities:    
Accounts receivable (1,019) (2,922)
Inventories (11,831) 478
Prepaid expenses and other (3,931) (4,184)
Accounts payable, accrued and other liabilities (2,843) (4,514)
Net cash used in operating activities (17,246) (6,963)
Cash flows from investing activities:    
Additions to property, plant and equipment (2,090) (2,152)
Additions to placement and evaluation units (3,442) (7,189)
Cash paid for acquisitions (540) (3,600)
Net cash used in investing activities (6,072) (12,941)
Cash flows from financing activities:    
Proceeds from borrowings on long-term debt 70,000 5,000
Repayment of long-term debt (45,000) 0
Deferred financing costs on long-term debt (751) 0
Proceeds from exercise of stock options and employee stock purchase plan 230 1,388
Net cash provided by financing activities 24,479 6,388
Effect of exchange rate changes on cash and cash equivalents (129) (354)
Increase (decrease) in cash and cash equivalents 1,032 (13,870)
Cash and cash equivalents at beginning of period 28,825 48,161
Cash and cash equivalents at end of period 29,857 34,291
Supplemental disclosure of non-cash investing and financing activities:    
Accrual for capital expenditures incurred during the period $ 113 $ 65